Agreements reached under this partnership
Business Alliance- 1
Various pharmacological efficacy studies
- 2
① Suppression of increases in intraocular pressure (glaucoma-related)
- 3
② Inhibition of angiogenesis (retinal disease-related)
- 4
③ Anti-inflammatory effects (strengthening the evidence for the mechanism of action)
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This matter will have no impact on the fiscal year ending March 2027.
| Item | Details |
|---|---|
| Name of alliance partner | National University Corporation, The University of Tokyo, Faculty of Medicine, Department of Ophthalmology |
| Alliance partner's business activities | The department has an extensive track record spanning basic to clinical research in ophthalmic diseases, including glaucoma and diabetic retinopathy. |
| Alliance partner's location | Bunkyo-ku, Tokyo |
| Type of alliance | Business Alliance |
| Details of the alliance | Various pharmacological efficacy studies, ① Suppression of increases in intraocular pressure (glaucoma-related), ② Inhibition of angiogenesis (retinal disease-related), ③ Anti-inflammatory effects (strengthening the evidence for the mechanism of action) |
| Contract Period | Extended from the scheduled end in July 2026 to the scheduled end in March 2027 |
| Alliance start date | July 2024 (joint research agreement executed) |
| Impact on Business Performance | This matter will have no impact on the fiscal year ending March 2027. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To compile the research findings related to RBM-006. The Company considers these results to be important progress that could lead to expanding indications to multiple ophthalmic diseases, establishing a differentiated position, and expanding future licensing and partnering opportunities, thereby contributing to an increase in pipeline value.